Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.69 |
| ▸ | TLR2 | O60603 | 2/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.40 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969872 | 1.00 | PRCP (0.69) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL6360674 | 1.00 | PRCP (0.69) | PRCPTLR2DPP7HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL3268154 | 0.98 | PRCP (0.68) | PRCPTLR2DPP7HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6163226 | 0.98 | PRCP (0.68) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL2794195 | 0.95 | PRCP (0.77) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL3289136 | 0.95 | PRCP (0.77) | PRCPTLR2DPP7HTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL11337287 | 0.93 | PRCP (0.74) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL9044288 | 0.90 | PRCP (0.80) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL8602848 | 0.90 | PRCP (0.80) | PRCPTLR2DPP7HTR2CHTR2B | |
| SCHEMBL6361143 | 0.89 | PRCP (0.74) | PRCPTLR2DPP7KDM4EEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CHEMOCENTRYX, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-05-10 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-8168654-B2 | Quinuclidine derivatives binding to mucarinic M3 receptors | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | COLLINGWOOD STEPHEN PAUL | 2010-02-18 | — | — | US | disclosed |
| EP-1631569-B1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | NOVARTIS AG (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | PRCP 2859/4885TLR2 906/4885DPP7 1895/4885 |
| US-20180127395-A1 | SUBSTITUTED BENZIMIDAZOLES AND BENZOPYRAZOLES AS CCR(4) ANTAGONISTS | CCR4, CCR1, CCR3 | PRCP 3192/4885TLR2 749/4885DPP7 2526/4885 |
| US-20100041887-A1 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | CHRM3, CHRM2, CHRM1 | PRCP 2859/4885TLR2 906/4885DPP7 1895/4885 |
| US-10647696-B2 | Substituted benzimidazoles and benzopyrazoles as CCR(4) antagonists | CCR4, CCR1, CCR3 | PRCP 3192/4885TLR2 749/4885DPP7 2526/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.